Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending

This study analyzes partial orphan cancer drugs’ development, approval, and economics.

Source: Value in Health - January 18, 2024 Category: International Medicine & Public Health Authors: Thomas Michaeli, Daniel Tobias Michaeli Tags: Health Policy Analysis Source Type: research